Polyclonal Antibody to Activin A Receptor Type II A (ACVR2A)
| Code | Size | Price |
|---|
| PAC117Hu01-20ul | 20ul | £87.00 |
Quantity:
| PAC117Hu01-100ul | 100ul | £162.00 |
Quantity:
| PAC117Hu01-200ul | 200ul | £218.00 |
Quantity:
| PAC117Hu01-1ml | 1ml | £499.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
ACVR2-A; ACTRII; ACTR-II; ACVR2
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Activin A Receptor Type II A
Reactivity:
Mu;Ra;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.5-3ug/mL;<br/>Immunohistochemistry: 5-30ug/mL;<br/>Immunocytochemistry: 5-30ug/mL;<br/>Optimal working dilutions must be determined by end user.
References
https://www.ncbi.nlm.nih.gov/pubmed/29193906; https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/abs/10.1002/dta.3378;
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Activin A Receptor Type II A (ACVR2A) | RPC117Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||